A strong team with experience and know-how

Management

Attila Strauss

Mr Attila Strauss studied International Trade Management (B.A.) and Information Technology with a focus on IT Security (M.Sc.) in Ingolstadt and Bochum. Before joining the group of companies, Mr Strauss worked for well-known companies in the field of process optimisation.

Board

Uwe Zimdars
Prof. Dr. med. Dirk Hempel
Prof. Dr. Dr. Sabine Meck

Latest news

| Investor News

  • Group revenue: +7.4% to EUR 364.3 million (FY 2024: EUR 339.2 million)
  • EBITDA: +23.6% to EUR 39.4 million (FY 2024: EUR 31.9 million)
  • EBIT: +29.2% to EUR 34.6 million (FY 2024: EUR 26.8 million)
  • EBIT margin: 9.5% (FY 2024: 7.9%)
  • EBT: +29.5% to EUR 34.1 million (FY 2024: EUR 26.3 million)
  • Earnings per share: EUR 1.19 (FY 2024: EUR 0.85)

| Investor News

M1 Kliniken AG announces that the sale of HAEMATO Pharm GmbH by its majority holding, HAEMATO AG (85%), to the PHOENIX group was successfully completed effective as of the end of January 31, 2026.

| Investor News

The Supervisory Board of M1 Kliniken AG has appointed Ms. Katharina Zimmnau to the Executive Board of M1 Kliniken AG with effect from 10. December 2025.

| Investor News

  • Group revenue: +6.7% to EUR 274.3 million (YTD Q3 2024: EUR 257.2 million)
  • EBITDA: +9% to EUR 28.2 million (YTD Q3 2024: EUR 25.9 million)
  • EBIT: +11% to EUR 24.5 million (YTD Q3 2024: EUR 22.1 million)
  • EBIT margin: 8.9% (YTD Q3 2024: 8.6%)
  • EBT: +10% to EUR 24.4 million (YTD Q3 2024: EUR 22.2 million)
  • Earnings per share: EUR 0.86 (YTD Q3 2024: EUR 0.77)